LSTA Profile
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing cellular therapies aimed at reversing disease and promoting tissue regeneration. The company's innovative pipeline includes several promising product candidates, each targeting significant medical needs. HONEDRA, a key asset, is undergoing Phase II clinical trials for critical limb ischemia and has earned the SAKIGAKE designation, a designation granted by the Japanese regulatory agency to expedite the development of groundbreaking therapies. XOWNA, another major candidate, is in Phase IIb trials for treating coronary microvascular dysfunction, a condition that significantly impacts cardiovascular health. Additionally, CLBS201 is a CD34+ cell therapy currently in development for pre-dialysis patients suffering from chronic kidney disease, addressing a critical need in nephrology.
Lisata Therapeutics, formerly known as NeoStem, Inc., rebranded as Caladrius Biosciences, Inc. in June 2015, and further changed its name to Lisata Therapeutics, Inc. on September 15, 2022. This rebranding reflects the company’s evolving focus and strategic direction in the biopharmaceutical landscape. The company’s therapeutic approach leverages advanced cellular technologies to target complex and challenging health conditions, emphasizing its commitment to innovation in regenerative medicine.
The company's research and development efforts are supported by its extensive experience and expertise in cellular therapy. Lisata Therapeutics employs cutting-edge technologies and a robust clinical development strategy to advance its therapeutic candidates from preclinical stages through clinical trials. The company’s focus on high-impact areas, such as cardiovascular disease and chronic kidney disease, positions it at the forefront of therapeutic innovation.
Headquartered in Basking Ridge, New Jersey, Lisata Therapeutics continues to drive forward with its mission to deliver transformative treatments. Its ongoing clinical trials and strategic development efforts underscore its commitment to addressing unmet medical needs and improving patient outcomes through advanced cellular therapies. As the company progresses through its clinical programs, it aims to make significant contributions to the field of regenerative medicine.
|
